$アドベラム・バイオテクノロジーズ(ADVM.US)$Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD 4 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE – Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints – – Preliminary safety data support a favorable benefit-risk pr...
$アドベラム・バイオテクノロジーズ(ADVM.US)$2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass. Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
1
1
報告
QianmengYuスレ主 :
so strange. If insider knew data is so great, they won’t finance at 1.2 with almost 100% dilution, Private placement will get 50% shares thereafter, insider get somewhat. That’s more shares than they can dump to open market. what’s point to pump to 2.8? I don’t think in current US regulations, someone can take over a company simply just by private share issuing and collecting sufficient shares on open market (allowed in some countries). Let’s see.
$アドベラム・バイオテクノロジーズ(ADVM.US)$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
1
報告
QianmengYu :
thank you. I am not surprised. Nasty.
$アドベラム・バイオテクノロジーズ(ADVM.US)$I’ll probably sell most position at $2. I feels like phase 2 is great, and they are working with some IB to do stock offering once news is out.
Dr. Corbau's appointment, with his gene therapy expertise, is seen as crucial for Adverum's Ixo-vec advancement towards pivotal trials and commercialization for treating wet AMD. He is eager to progress Adverum's early-stage research assets and sees Ixo-vec as a potential leading therapy for wet AMD.
アドベラム・バイオテクノロジーズに関するコメント
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
Update
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
Sold half at 1.8 but chart look good
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
$アイポイント・ファーマシューティカルズ(EYPT.US)$
$アドベラム・バイオテクノロジーズ(ADVM.US)$
$リジェネックスバイオ(RGNX.US)$
$4Dモレキュラー・セラピューティクス(FDMT.US)$
$コディアック・サイエンシズ(KOD.US)$
feels like insider action.
まだコメントはありません